Sprint Bioscience
1.44 SEK 0%1 investor is following this company
Sprint Bioscience is a research company. The company develops pharmaceutical candidates that alone or in combination with other pharmaceuticals can fight cancer. The company has a project portfolio focused on attacking parts of cancer cell processes. The company's business model is based on developing projects parallel in the preclinical phase to subsequently enter into licensing agreements with the global pharmaceutical industry. The company was founded in 2009 and is headquartered in Huddinge.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SPRINT
Daily low / high price
1.294 / 1.444
SEK
Market cap
100.54M SEK
Turnover
66.4K SEK
Volume
49K
Financial calendar
Interim report
28.08.2024
Interim report
30.10.2024
Annual report
12.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
First Venture Sweden | 14.1 % | 14.1 % |
Nordnet Pensionsförsäkring | 10.0 % | 10.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Positive preclinical results in Sprint Bioscience's oncology program targeting TREX1
New data from the VPS34 program published
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools